Todas las investigaciones
ReclutamientoOBSERVACIONAL

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

This study is for people with haemophilia B. It's called an 'observational' study, meaning researchers will watch and collect information about how people are doing over time, rather than trying a new treatment in a controlled way. The main goal is to understand how well a new gene therapy called HEMGENIX works and if it's safe for people with haemophilia B, both shortly after treatment and for many years to come. The study will also look at a group of patients who are receiving a standard treatment called Factor IX (FIX) prophylaxis. This comparison will help doctors understand the benefits and any potential downsides of HEMGENIX more clearly. It's about gathering real-world information to help future patients.

De un vistazo

Estado
Reclutamiento
Patrocinador
CSL Behring
Objetivo de inscripción
500
Inicio
15 Jun 2023
Estimación de finalización
01 Aug 2043

¿De qué trata este estudio?

This study wants to learn more about a treatment called HEMGENIX for people who have haemophilia B. Haemophilia B is a rare inherited condition where your blood doesn't clot properly, leading to longer bleeding after an injury or surgery, and sometimes bleeding inside the body.

HEMGENIX is a type of gene therapy. This means it aims to help your body produce the missing clotting factor (Factor IX) itself, rather than needing regular injections of it. Because HEMGENIX is a newer treatment, doctors want to carefully watch people who receive it to understand how well it works over many years and if there are any long-term side effects or safety concerns. This study is like following a group of people over time to see how the treatment affects their health and quality of life.

The study also includes another group of people with haemophilia B who are having standard treatment with Factor IX (FIX) shots. By comparing the HEMGENIX group with the FIX group, researchers can get a clearer picture of how HEMGENIX performs compared to what's already available. This helps ensure that doctors have the best possible information when advising patients about their treatment options.

Puntos clave

  • This study observes real-world use of HEMGENIX for haemophilia B.
  • It aims to understand long-term effectiveness and safety.
  • It also collects data on standard Factor IX prophylaxis for comparison.
  • Participation involves sharing medical information from routine care.
  • It's for adults (18+) with haemophilia B.
  • The findings will help improve future treatment decisions for haemophilia B.

¿Quién puede ser elegible?

To be part of this study, you would need to be 18 years old or older. There are two main groups of people the study is observing.

One group is for people who have already had the HEMGENIX treatment commercially, meaning they received it as a standard medical treatment, not as part of a clinical trial. You would need to agree to join the study either shortly before or within six months of having your HEMGENIX treatment, or within six months of when your local clinic starts participating in the study.

The other group is for adult patients with haemophilia B who are currently receiving regular injections of Factor IX (FIX) to prevent bleeding. For this group, you would need to already be part of a specific health registry, like ATHN Transcends Haemophilia Cohort, or a similar one.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Do you have haemophilia B?
  2. ¿Tienes 18 años o más?
  3. Have you recently received HEMGENIX treatment, or are you planning to?
  4. Or, are you currently on regular Factor IX (FIX) prevention treatment and part of a specific health registry?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

This is an observational study, which means you won't be given a new treatment specifically for the study. Instead, researchers will collect information from your regular medical check-ups and records. If you've received HEMGENIX, they'll monitor how you're doing over time. This involves reviewing your health records from your doctor visits, which will include details about any bleeding episodes you have, how much Factor IX you might still need (if any), and any side effects you experience. For those on standard Factor IX treatment, similar information will be gathered. The study aims to follow participants for a long time to understand the long-term effects of treatments.

Riesgos y beneficios potenciales

Because this is an observational study, you won't be taking a new experimental drug, so the risks are generally associated with sharing your health information. All personal data will be kept confidential. Potential benefits include helping doctors and researchers understand more about haemophilia B treatments, especially HEMGENIX, which could improve care for future patients. You have the right to withdraw from the study at any time without affecting your medical care.

Ubicaciones (12)

  • American Thrombosis and Hemostasis Network
    Código postal verificado
    Rochester, United States· Reclutamiento
  • Medical University Vienna
    Código postal verificado
    Viena, Austria· Reclutamiento
  • Aarhus Universitetshospital
    Solo ciudad
    Århus N, Denmark· Reclutamiento
  • Centre Hospitalier Universitaire de Brest / CHU Morvan
    Código postal verificado
    Brest, France· Reclutamiento
  • Centre Régional de Traitement de l'Hémophilie
    Código postal verificado
    Nantes, France· Reclutamiento
  • CHU Nancy - Hôpital Brabois
    Código postal verificado
    Vandœuvre-lès-Nancy, France· Reclutamiento
  • Klinik für Angiologie/ Hämostaseologie
    Código postal verificado
    Berlín, Alemania· Reclutamiento
  • University of Clinic Bonn
    Código postal verificado
    Bonn, Alemania· Reclutamiento
  • Klinikum der Johann-Wolfgang Goethe Universitaet
    Código postal verificado
    Fráncfort, Alemania· Reclutamiento
  • Hannover Medical School
    Código postal verificado
    Hanóver, Alemania· Reclutamiento
  • Hospital Alvaro Cunqueiro Dr. Manuel Rodriquez-Lopez
    Código postal verificado
    Vigo, Spain· Reclutamiento
  • University Hospital Bern Inselspital
    Código postal verificado
    Bern, Switzerland· Reclutamiento

Preguntas comunes

What is haemophilia B?

Haemophilia B is a genetic condition where your blood doesn't clot properly due to a lack of a specific protein called Factor IX. This can cause prolonged bleeding.

What is HEMGENIX?

HEMGENIX is a gene therapy that aims to help people with haemophilia B produce their own Factor IX, potentially reducing the need for regular injections.

¿Tendré que tomar nuevos medicamentos para este estudio?

No, this is an 'observational' study. You will continue with your current medical care, and the researchers will simply gather information about your health.

How long will I be part of this study?

This study looks at long-term effects, so it will follow participants for several years to understand how treatments work over time.

What's the difference between this study and a clinical trial?

In an observational study, doctors watch what's already happening and record it. In a clinical trial, people are often given a new treatment to test its effects.

Cómo obtener más información

Trial Registration Coordinator

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "An Observational Cohort Study to Characterize the Effectiven…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.